81 related articles for article (PubMed ID: 35459800)
1. MYC targeting by OMO-103 in solid tumors: a phase 1 trial.
Garralda E; Beaulieu ME; Moreno V; Casacuberta-Serra S; Martínez-Martín S; Foradada L; Alonso G; Massó-Vallés D; López-Estévez S; Jauset T; Corral de la Fuente E; Doger B; Hernández T; Perez-Lopez R; Arqués O; Castillo Cano V; Morales J; Whitfield JR; Niewel M; Soucek L; Calvo E
Nat Med; 2024 Mar; 30(3):762-771. PubMed ID: 38321218
[TBL] [Abstract][Full Text] [Related]
2. Strategies to overcome low MHC-I expression in paediatric and adult tumours.
Guillaume J; Perzolli A; Boes M
Immunother Adv; 2024; 4(1):ltad028. PubMed ID: 38223409
[TBL] [Abstract][Full Text] [Related]
3. Advancing cancer immunotherapy: from innovative preclinical models to clinical insights.
Craig AW; Frieboes HB; Videira PA
Sci Rep; 2024 Jan; 14(1):1205. PubMed ID: 38216668
[TBL] [Abstract][Full Text] [Related]
4. Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer.
Koukourakis IM; Xanthopoulou E; Sgouras TI; Kouroupi M; Giatromanolaki A; Kouloulias V; Tiniakos D; Zygogianni A
Br J Cancer; 2023 Nov; 129(11):1852-1862. PubMed ID: 37838813
[TBL] [Abstract][Full Text] [Related]
5. Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E
Explor Target Antitumor Ther; 2023; 4(3):474-497. PubMed ID: 37455828
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy.
Han J; Wu M; Liu Z
Front Immunol; 2023; 14():1190333. PubMed ID: 37275859
[TBL] [Abstract][Full Text] [Related]
7. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer.
Lin M; Sun X; Lv L
Mol Ther Oncolytics; 2023 Jun; 29():91-106. PubMed ID: 37215386
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert.
Li X; Gulati M; Larson AC; Solheim JC; Jain M; Kumar S; Batra SK
Semin Cancer Biol; 2022 Nov; 86(Pt 2):14-27. PubMed ID: 36041672
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.
Korentzelos D; Wells A; Clark AM
Sci Rep; 2022 Apr; 12(1):6657. PubMed ID: 35459800
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract][Full Text] [Related]
12. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
Markowski MC; Shenderov E; Eisenberger MA; Kachhap S; Pardoll DM; Denmeade SR; Antonarakis ES
Prostate; 2020 Apr; 80(5):407-411. PubMed ID: 31972048
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Sharma P; Pachynski RK; Narayan V; Fléchon A; Gravis G; Galsky MD; Mahammedi H; Patnaik A; Subudhi SK; Ciprotti M; Simsek B; Saci A; Hu Y; Han GC; Fizazi K
Cancer Cell; 2020 Oct; 38(4):489-499.e3. PubMed ID: 32916128
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
